This study aims to compare the pharmacokinetics and safety following administration of DWJ1567 and DWC202312 in healthy volunteers
The study design is a Randomized, Open-label, Oral, Single-dose, Four-way crossover study. The patients were randomly assigned to each group. Primary endpoint was Cmax and AUCt of DWJ1567 and DWC202312. Secondary endpoints were AUCinf, Tmax, t1/2 of DWJ1567 and DWC202312.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
44
H Plus YANGJI Hospital
Seoul, South Korea
RECRUITINGCmax,ss of DWJ1567 and DWC202312
Time frame: At pre-dose (0 hour), and post-dose 0 to 72 hour.
AUCt of DWJ1567 and DWC202312
Time frame: At pre-dose (0 hour), and post-dose 0 to 72 hour.
AUCinf of DWJ1567 and DWC202312
Time frame: At pre-dose (0 hour), and post-dose 0 to 72 hour
Tmax of DWJ1567 and DWC202312
Time frame: At pre-dose (0 hour), and post-dose 0 to 72 hour
AUCt/AUCinf of DWJ1567 and DWC202312
Time frame: At pre-dose (0 hour), and post-dose 0 to 72 hour
t1/2 of DWJ1567 and DWC202312
Time frame: At pre-dose (0 hour), and post-dose 0 to 72 hour
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.